TickerTalks
Browse all tickers →
TickerTalks›$NBP
NBNBP

NovaBridge Biosciences

$NBP·$202M·Biotechnology·Healthcare
$1.96+3.2%YTD-60.6%1Y-62.0%
Mentions · last 7 days
2026-08-08: 0 posts2026-08-09: 0 posts2026-08-10: 0 posts2026-08-11: 0 posts2026-08-12: 0 posts2026-08-13: 0 posts2026-08-14: 1 posts1
Price updated 1d ago·X counts updated 22h ago
NBNBP
$NBPNovaBridge Biosciences
$1.96+3.16%1 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $NBP, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-14

Falling on heavy selling — points lower unless it turns around.

NovaBridge Biosciences is a $202M pre-revenue biotech at 8% of range — Q2 EPS -$0.22 vs -$0.008 est (-2,660% miss).

NovaBridge Biosciences is a small-cap clinical-stage biotech. $202M mcap, price $1.90, YTD -60.6%, t12m -55.2%, sitting at just 8% of the 52-week range — deep drawdown.

What's happening:

  • Revenue is $0 (pre-commercial).
  • Q2 2026 (7/30) EPS -$0.22 vs -$0.008 est (-2,660% miss) — massive miss on losses.
  • Prior quarter -$0.08 vs -$0.06 est (-33% miss).
  • 8/12 news: 'NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026' — imminent print.
  • 6/x news: 'NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026'.
  • One unrelated news item (Woodside Energy) is likely a data-source cross-contamination.
  • No X sentiment sample, no filings, no insider signal, no analyst estimates.
  • PE -22.8x meaningless, ROE -0.6%.

What you're watching: First half 2026 print 8/20 (cash-runway commentary, pipeline update), 9/8 annual general meeting, and any capital-raise announcement.

What to watch: First half 2026 print 8/20 (cash runway), 9/8 AGM, and any capital-raise.

On the calendar: 2026-08-20 — First Half earnings

no sentimentpre revenue

Read the AI verdict + X sentiment for $NBP

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage immuno-oncology biotech developing bispecific antibodies including givastomig for gastric cancer and related targeted therapies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NBP.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NBP

Partial — Clinical-stage immuno-oncology biotech developing bispecific antibodies including givastomig for gastric cancer and related targeted therapies; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-94.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-0.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$-0.22$-0.01-2660.4%
Q3 2025Dec 18, 2025$-0.08$-0.06-33.3%
Q2 2025Aug 26, 2025$-0.03$-0.06+58.3%
Q1 2025May 15, 2025$-0.02$-0.06+68.4%

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0———$-0.09$-14.6M
Q3 FY25$0———$-0.16$13.1M
Q2 FY25$0———$-0.07$0
Q1 FY25$0———$-0.28$0

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$3.29-$3.29 – -$3.290
FY27$0$0 – $0-$4.96-$4.96 – -$4.960
FY28$106.6M$106.6M – $106.6M-$5.29-$5.29 – -$5.292
FY29$167.8M$167.8M – $167.8M-$5.80-$5.80 – -$5.801
FY30$436.1M$436.1M – $436.1M-$5.33-$5.33 – -$5.331

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-32.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 42.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 6Xu Cong ClaireSVP, Clinical Development4.5K sh$4KSellJun 18Dennis Phillip AndrewChief Medical Officer8.5K sh$6KSellJun 1Xu Cong ClaireSVP, Clinical Development3.5K sh$14KSellMay 14Cao Sean WuxiongSee Remarks21.4K sh$43KBuyApr 24Hagler Mark ArnoldSee Remarks230.0K sh$577K
+ 8 other (5 awards · 3 exempts) in window

See when $NBP insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 83
AI summary

Initial Form 3 ownership statement filed by Srishti Gupta, a newly reportable officer or director at NovaBay Pharmaceuticals (NBP), disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying role. No operational implications for the company.

3New insider — initial holdingsApr 223
3/ANew insider — initial holdingsApr 103/A
3New insider — initial holdingsApr 13
3New insider — initial holdingsMar 243
3New insider — initial holdingsMar 193
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 27 other (13 6-Ks · 12 3s · 1 20-F/A · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026globenewswire.com·2d agoWoodside Energy Second Quarter Report for Period Ended 30 June 2026gurufocus.com·18d agoNovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026globenewswire.com·22d agoI-Mab (NASDAQ:NBP) Trading Down 4.9% – Time to Sell?defenseworld.net·24d agoNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officerglobenewswire.com·48d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · last 7 days

No standout posts about $NBP on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport